Blockchain Registration Transaction Record

Hemogenyx Pharmaceuticals CEO Dr. Vladislav Sandler outlines 2023 progress with HEMO-CAR-T

Hemogenyx Pharmaceuticals CEO Dr. Vladislav Sandler discusses the company's significant progress with its HEMO-CAR-T product candidate in 2023, including the submission of an IND application to the FDA and a successful fundraising round.

Hemogenyx Pharmaceuticals CEO Dr. Vladislav Sandler outlines 2023 progress with HEMO-CAR-T

The progress made by Hemogenyx Pharmaceuticals with its HEMO-CAR-T product candidate in 2023 is important as it signifies advancements in the treatment of relapsed refractory acute myeloid leukemia. This news impacts individuals interested in innovative cancer treatments and investors in the biopharmaceutical industry.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xba58eda26edd24b3400d43c7941a4feef90fcba5fd0d2c2f7c088212ff15b0c6
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintvibev9eN-a30993caf7d79385245a9d3433adca54